Skip to main content

First-Line Osimertinib/Bevacizumab for Metastatic EGFR-Mutant Lung Cancer

*July 2020*

In the trial, 49 patients enrolled between August 2016 and May 2018 at Memorial Sloan Kettering Cancer Center received osimertinib at 80 mg daily and bevacizumab at 15 mg/kg once every 3 weeks, the maximum-tolerated dose identified in the phase I portion of the trial.

The primary outcome measure was progression-free survival at 1 year, with the treatment strategy to be considered promising with improvement from a historical rate of 51% to a rate of 70%. Read more.